In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Existing backers participate in NeoVista's $18mm Series D

Executive Summary

Returning shareholders Essex Woodlands, Versant Ventures, SV Life Sciences, Accuitive Medical Ventures, MPM Capital, and the Carlyle Group have provided $18mm in Series D funding to NeoVista, which is in the late stages of developing a beta radiation-delivering device in combination with the anti-VEGF drug Avastin for wet age-related macular degeneration.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies